Table 3 Number of patients with at least one adverse event (> 5%), according to intensity
Masitinib treatment (n= 26) | Placebo (n= 8) | |||
|---|---|---|---|---|
All | Severe | All | Severe | |
At least one adverse event | 17 (65%) | 4 (15%) | 3 (38%) | 1 (13%) |
Oedema - all | 8 (31%) | |||
Diarrhoea | 6 (23%) | |||
Rash - all | 5 (19%) | 2 (8%) | ||
Anorexia | 4 (15%) | 2 (8%) | ||
Nausea | 4 (15%) | 1 (4%) | ||
Vomiting | 3 (12%) | |||
Asthenia | 3 (12%) | 1 (4%) | ||
Bronchitis | 2 (8%) | |||
Weight decreased | 2 (8%) | 1 (13%) | ||
Transaminases increased | 2 (8%) | 1 (4%) | ||
Arthralgia | 2 (8%) | |||
Depression | 2 (8%) | 1 (13%) | ||
Balance disorder | 1 (13%) | 1 (13%) | ||